Article
A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881
Review Compares Psoriasis Therapies in Asian Populations